Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Quantumscape Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Quantumscape Corp trades at $3.89 (market cap $2.55B). The key difference: Dyne Therapeutics Inc. Common Stock and Quantumscape Corp are close in size by market cap, and Quantumscape Corp is more actively traded (12,145,789 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Quantumscape Corp for 37 Days on average.
| DYN | QS | |
|---|---|---|
Market Cap | $2.86B | $2.55B |
Volume | 3,341,579 | 12,145,789 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $18.44 |
52-Week Low | $14.60 | $3.93 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $2.18B | $1.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
QuantumScape (QS) trades at $4.12, down 3.51% with a bearish technical outlook despite oversold RSI readings. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative ROE/ROA. Recent news highlights commercialization delays and insider selling, while analyst consensus shows 73% hold ratings with a $10.35 price target representing 151% upside potential.
QS presents high-risk speculation with substantial upside if solid-state battery technology succeeds, but faces execution risks and cash burn. The stock trades near 52-week lows with negative cash flow trends, requiring careful risk management given the 5+ year commercialization timeline and competitive threats in EV battery development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
